(2)
Registration For This FREE Tribe Public Presentation and Q&A Event Is Now Open at NeuBase22.TribePublic.com
SAN FRANCISCO, CA / ACCESSWIRE / December 18, 2020 / Tribe Public announced today that Dietrich Stephan, Ph.D., Chief Executive Officer of NeuBase Therapeutics, Inc. (NASDAQ:NBSE), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, will present at Tribe Public s Presentation and Q&A Webinar Event beginning at 8:30 a.m. PDT / 11:30 a.m. EDT on Tuesday, December 22, 2020.
During this complimentary, 30-minute event, Dr. Stephan will deliver his presentation titled Accelerating the Genetic Revolution with a New Class of Synthetic Medicines. He will also be available for a brief Q&A session. To register for the complimentary event, please visit
Specific genetic target could help explain the variation in COVID-19 effects
The Translational Genomics Research Institute (TGen), an affiliate of City of Hope, has identified a specific genetic target that could help explain the tremendous variation in how sick those infected with COVID-19 become.
The study results, recently published in the journal
mSphere, describe a molecule made from DNA miR1307 as a potential dimmer switch that may influence the severity of the disease; why some infected with SARS-CoV-2, the virus that causes COVID-19, have mild or even no symptoms, while others become seriously ill or die.
Led by Nicholas Schork, Ph.D., a Distinguished Professor and Director of TGen s Quantitative Medicine and Systems Biology Division, researchers identified miR1307 by comparing the genetic elements of SARS-Cov-2 with seven other human coronaviruses, some of which merely cause common colds. In addition, they examined the genomes of coronavirus strains known to infect
E-Mail
PHOENIX, Ariz. Dec. 15, 2020 The Translational Genomics Research Institute (TGen), an affiliate of City of Hope, has identified a specific genetic target that could help explain the tremendous variation in how sick those infected with COVID-19 become.
The study results, recently published in the journal
mSphere, describe a molecule made from DNA miR1307 as a potential dimmer switch that may influence the severity of the disease; why some infected with SARS-CoV-2, the virus that causes COVID-19, have mild or even no symptoms, while others become seriously ill or die.
Led by Nicholas Schork, Ph.D., a Distinguished Professor and Director of TGen s Quantitative Medicine and Systems Biology Division, researchers identified miR1307 by comparing the genetic elements of SARS-Cov-2 with seven other human coronaviruses, some of which merely cause common colds. In addition, they examined the genomes of coronavirus strains known to infect bats, pigs, pangolins, ferrets, civ
Identifying a gene that could explain disparity in COVID-19 effects medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.
Compound derived from thunder god vine could improve outcomes for pancreatic cancer patients
The results of a pre-clinical study led by researchers at the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, suggest how a compound derived from the thunder god vine an herb used in China for centuries to treat joint pain, swelling and fever is able to kill cancer cells and potentially improve clinical outcomes for patients with pancreatic cancer.
The medicinal plant s key ingredient, triptolide, is the basis of a water-soluble prodrug called Minnelide, which appears to attack pancreatic cancer cells and the cocoon of stroma surrounding the tumor that shields it from the body s immune system. Investigators recently published the study results in the journal